Ocrelizumab/hyaluronidase

< Ocrelizumab

Ocrelizumab/hyaluronidase
Combination of
OcrelizumabMonoclonal antibody
HyaluronidaseEndoglycosidase
Clinical data
Trade namesOcrevus Zunovo
AHFS/Drugs.comOcrevus-zunovo
License data
Routes of
administration		Subcutaneous
ATC code
  • None
Legal status
Legal status

Ocrelizumab/hyaluronidase, sold under the brand name Ocrevus Zunovo, is a fixed-dose combination medication used for the treatment of multiple sclerosis. It contains ocrelizumab, a recombinant humanized monoclonal antibody directed at CD20; and hyaluronidase (human recombinant), an endoglycosidase. It is taken by subcutaneous injection.

Ocrelizumab/hyaluronidase was approved for medical use in the United States in September 2024.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.